Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptazocine SCHEMBL29388574 | 1.00 | HSD11B1 (0.51) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL1650016 | 1.00 | HSD11B1 (0.51) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL9487496 | 0.99 | HSD11B1 (0.50) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL30901223 | 0.99 | HSD11B1 (0.50) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| Eptazocine SCHEMBL395495 | 0.99 | HSD11B1 (0.50) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL11651818 | 0.82 | SIGMAR1 (0.44) | OPRK1OPRD1SIGMAR1 | |
| SCHEMBL9488119 | 0.82 | HSD11B1 (0.52) | HSD11B1OPRM1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL30945838 | 0.82 | SIGMAR1 (0.41) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL20394548 | 0.82 | HSD11B1 (0.52) | HSD11B1OPRM1OPRK1SIGMAR1MRGPRX2 | |
| Bromide SCHEMBL11653724 | 0.81 | OPRM1 (0.50) | HSD11B1OPRM1OPRK1OPRD1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7680 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | claimed |
| US-20250017846-A1 | TOPICAL ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-16 | — | — | US | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| EP-0848960-A2 | Adhesive for dermal or transdermal therapy systems | RÖHM GMBH (DE) | 1998-06-24 | — | — | EP | claimed |
| EP-0848950-A2 | Adhesive and binder compositions based on a (meth)acrylate polymer, an organic acid and a plasticiser | RÖHM GMBH (DE) | 1998-06-24 | — | — | EP | claimed |
| WO-1997033566-A2 | COMPOSITION AND DOSAGE FORM COMPRISING OPIOID ANTAGONIST | ALZA CORPORATION (US) | 1997-09-18 | — | — | WO | claimed |
| EP-0785775-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | claimed |
| EP-0731694-A4 | — | — | 1996-10-02 | — | — | EP | claimed |
| EP-0731694-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | Euroceltique S.A. (LU) | 1996-09-18 | — | — | EP | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| WO-1996014058-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 1996-05-17 | — | — | WO | claimed |
| WO-1995014460-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 1995-06-01 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |